Natreon’s Capros® shown to have protective effects against myocardial ischemia-reperfusion injury
FOR IMMEDIATE RELEASE
New Brunswick, NJ, September 2015 – Natreon’s Capros®, a clinically studied and standardized aqueous extract of Phyllanthus emblica, has shown to preserve cardiac tissue during ischemiareperfusion injury in rats according to a study just published in The Journal of Physiology and Biochemistry. This study was designed to examine the effect of Capros® treatment on myocardial ischemia-reperfusion (I/R) and identify the molecular targets and its underlying mechanisms. Experimental animals were divided into four groups: control sham (CS), P. emblica sham (PS), control I/R (CIR), and P. emblica I/R (PIR). Rats in the P. emblica groups were gavaged with aqueous P. emblica solution (100 mg/kg body weight) for 30 days. After 30 days of gavaging, the I/R group underwent I/R surgery (45-min ischemia) followed by 4 or 30 days of reperfusion. Rats in the sham group underwent surgery without ligation. Left ventricular tissue samples, 4 and 30 days after I/R, were used for Western blot analysis and immunohistochemistry, respectively. Echocardiography showed increased ejection fraction and fractional shortening and decreased left ventricular internal diameter in experimental subjects compared to controls. There was decreased fibrosis in P. emblica-treated rats compared to controls. The results of this study indicate that P. emblica is capable of upregulating the PI3K/Akt/GSK3β/β-catenin cardioprotective pathway, thereby preserving cardiac tissue during ischemia-reperfusion injury.
Capros® is a FDA GRAS approved, non-GMO, vegetarian ingredient derived from the edible fruits of Phyllanthus emblica. Previous randomized, double blind, placebo-controlled studies with Capros® treatment have shown significant benefits for cardiovascular health. These studies showed significant improvements in endothelial function by increasing production of nitric oxide by more than 50%. A significant decrease in the inflammation biomarker hsCRP by more than 50% was noted in these studies. In addition, triglyceride levels decreased, LDL decreased, and HDL increased in patients treated with Capros®. Capros® is a super antioxidant that is water soluble and stable; thus, it is an ideal product for addition into hot and cold beverages and functional foods.
About Natreon, Inc.: Natreon Inc. is a 16 year old company located in New Jersey with a state of the art R&D facility in Kolkata, India, and is focused on developing and marketing Ayurvedic products backed by extensive research, high degree of standardization, multiple clinical studies, safety studies, and intellectual property. Natreon’s R&D team is headed by Prof. Shibnath Ghosal, a Fulbright scholar and an eminent natural product chemist with hundreds of publications in scientific journals and a group of Ph.D. and Master’s level scientists. Natreon’s scientific research includes process optimization, development of chromatographic analytical methods such as HPLC, HPTLC, GC-MS and LC-MS for standardization, development of marker compounds, and pharmacological studies. Safety studies are done in the USA and clinical studies are conducted in reputed institutes in India as well as the USA. For more information on Capros® and Natreon’s other patented ingredients, please visit www.natreoninc.com. Natreon, Inc. Key Executives: Dr. Sanni Raju – CEO/Chairman Jeff Lind – VP Sales and Marketing Dr. Aparna Kalidindi – Manager, Technical Sales and Marketing
For more information on Capros® and Natreon’s other patented ingredients, please visit www.natreoninc.com.
Natreon, Inc. Key Executives: Dr. Sanni Raju – CEO/Chairman
Jeff Lind – VP Sales and Marketing Dr.
Aparna Kalidindi – Manager, Technical Sales and Marketing